∗Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria do Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia

†Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia

‡Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Brazil

§Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA

Conflicts of Interest and Source of Funding: This study was supported by a grant from Programa Pesquisa para o SUS (PPSUS/BA—research grant number 003/2017), a public research-funding program, and by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brazil (CAPES)—Finance Code 001. The sponsors had no role in either the study design, the writing of the manuscript, or the decision to submit it for publication. In addition, the University Hospital involved provided hospital structure, medications, and human resources. L.C.Q. reports consulting fees from Abbot, Allergan, Cristalia, Janssen Pharmaceutical, and Lundbeck and research fees from Janssen Pharmaceutical.

Address correspondence and reprint requests to Lucas C. Quarantini, MD, PhD, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Rua Dr. Augusto Viana, s/n – Canela, Salvador, Bahia, Brazil. Zip code: 40110-060; E-mail: [email protected]

The datasets analyzed during the present study are not publicly accessible but are available from the corresponding author on reasonable request.